Contrary to the previous study, another work reports that, in patients with hepatocellular carcinoma, a high level of phosphorylated ERK1/2 within tumors is associated with an increased number of PD-1− CD8+ T-lymphocytes and with a higher overall survival rate compared to patients with low phosphorylated ERK1/2 [151]. This evidence concerns the gene MAPK3 and hepatocellular carcinoma.